- TRADE NAME: Xtandi (Medivation)
- INDICATIONS: Metastatic castration-resistant prostate cancer in patients who have previously received docetaxel
- CLASS: Androgen antagonist
- HALF-LIFE: 8–9 days
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Alfentanil, Bosentan, Carbamazepine, Copanlisib, Cyclosporine, Dihydroergotamine, Doravirine, Doravirine/Lamiduvine/Tenofovir Disoproxil, Efavirenz, Ergotamine, Fentanyl, Fostemsavir, Gemfibrozil, Itraconazole, Midazolam, Midostaurin, Modafinil, Nafcillin, Neratinib, Omeprazole, Phenobarbital, Phenytoin, Pimozide, Quinidine, Rifabutin, Rifampin, Rifapentine, Sirolimus, St John's Wort, Tacrolimus, Warfarin - PREGNANCY: not indicated for use in women
Please login to view the rest of this drug profile.
DRUG REVIEW ARTICLE
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of enzalutamide in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 02/03/2024